Erdafitinib

Erdafitinib is an orally available, small-molecule, pan-fibroblast growth factor receptor (FGFR1–4) tyrosine kinase inhibitor approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma harboring specific FGFR2 or FGFR3 alterations, usually after progression on platinum-based chemotherapy. It prevents tumor cell growth and angiogenesis by competitively binding to the ATP-binding site of FGFR kinases, thus blocking downstream FGFR signaling required for cancer cell proliferation and survival. Patient selection is guided by the presence of actionable FGFR mutations or fusions, using FDA-approved companion diagnostic tests.

Other names

BalversaJNJ-42756493JNJ 42756493890E37NHMV

Erdafitinib is a potent inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinases (specifically FGFR1, FGFR2, FGFR3, and FGFR4), blocking downstream signaling that would otherwise drive tumor growth, survival, and angiogenesis.